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Implantable cardioverter defibrillators (ICD) are highly effective in the prevention of sudden 
arrhythmic deaths. [1-3] The recurrence rate following an out of hospital  cardiac arrest or 
ventricular tachycardia is as high as 24-44% over the ensuing 18-36 months that secondary 
prevention is an important consideration in patients without a clearly defined reversible cause 
such as acute ischemia or major metabolic derangement. In this context, the ICD has been 
shown to be superior to anti-arrhythmics drugs including amiodarone, in a number of clinical 
trials.  [1,4,5] The value of an ICD is probably better expressed as the numbers needed to treat 
(NNT) to save a life. In the AVID trial, 9 patients had to be treated to save a life over a period 
of 3 years. The use of ICDs for primary prevention in patients at high risk for arrhythmic 
events  is  more controversial.  The event  rate  is  lower,  and the benefit  less  pronounced as 
reflected in a larger NNT. In the MADIT II trial of patients with coronary artery disease and 
severe LV dysfunction, the NNT was 18 to save one life over a period of 20 months. In the 
SCD-HeFT study of heart failure patients with LVEF < 0.35, the NNT was 14 over 5 year. In 
all cases, a non-arrhythmic cause limiting life expectancy to less than 1 year rarely justifies 
the use of an ICD. The use of ICDs in patients with advanced age, the subject of this editorial,  
is  not  well  defined  in  clinical  trials  either  because  of  exclusion  for  age  over  80  or  low 
representation of this age group. The current "appropriate use" guidelines suggest that an ICD 
may be appropriate  in  patients  over  the  80 years,  based on individual  considerations.  [6]
ICDs have a flip side. They are expensive and are associated with negative effects on quality 
of life. The adverse effects of an ICD include inappropriate shocks, infections, and hardware 
malfunction  including  the  highly  publicized  recall  advisories.  Inappropriate  shocks  are  a 
major cause of depression and post-traumatic stress disorder. Thus, the benefit of mortality 
reduction from an ICD comes at the cost of some morbidity. In addition, there appears to be a 
critical window in the course of heart disease when the ICD is most effective. In the AVID 
trial, the largest of the secondary prevention studies, benefit was mostly confined to patients 
with  left  ventricular  ejection  fraction  between  0.20  and  0.35.  Sudden  deaths  form  an 
important component of heart failure mortality in individuals with better functional class and 
these patients stand to benefit most from an ICD. The value of the ICD recede as heart failure 
worsens;  pump  failure  and  electromechanical  dissociation  takes  over  as  the  predominant 
component  of death in  NYHA class IV heart  failure.  In the absence of an indication for 
cardiac  resynchronization  therapy,  implanted  defibrillators  confer  minimal  benefit  in 
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advanced heart failure unless transplantation or long term assist devices are planned. [6]          
In  the  current  issue  of  the  journal,  Wilson  et  al.  [7]  present  analysis  of  a  single  center 
experience  with ICD implantation  in  octogenarians  in the United Kingdom over a 6 year 
period to 2012. For unclear  reasons,  only data  on 50 of 74 ICD recipients  are  presented. 
Annual mortality for the cohort was 14% representing a higher than usual mortality for an 
ICD population. Interestingly, most documented deaths were non-cardiac (5 patients died with 
pneumonia) reflecting co-morbidities and increased susceptibility to fatal infections in this age 
group. The data from the present study are largely in concert with prior publications of the use 
of  ICDs  in  elderly  patients.  [6,  8]                                    
Although mortality  from cardiovascular  disease has declined,  the total  disease burden has 
increased. People live longer but tend to be sicker. While the use of an ICD for secondary 
prevention is philosophically more acceptable for an otherwise healthy elderly patient, the use 
of the ICD for primary prevention generates more debate. Older patients are known to be at 
higher risk for sudden death. In addition, resuscitation from a cardiac arrest of the elderly is 
more likely to result in neurological damage and disability. Preventive measure would thus, be 
expected  to  be  most  effective  for  this  population.  However,  these  arguments  have  to  be 
tempered against the fact that the elderly have a higher mortality from non-arrhythmic causes 
and the ICD may merely convert a sudden death to a non-sudden, potentially more distressing 
mode  of  demise.  Against  this  backdrop  must  be  included  the  wishes  of  a  well-informed 
patient. An analysis based on SCD-HeFT and MADIT trials derived the following scenario for 
every 100 patients undergoing primary prevention ICD over a period of 5 years:  30 will die 
non-arrhythmic deaths, 7-8 patients will be saved by the ICD, 15-20 will receive a shock they 
do not need, 5-15 will experience other complications from the device, and the rest will not 
experience their device at all. [9] Explained in such terms, a patient is better placed to balance 
the risks and benefits of a device that often adds little to quality of life and has a modest effect 
on  extending  longevity.                                                      
Finally, we all recognize that the trajectory of senescence with advancing age is not always 
linear or uniform. Many 80 year-olds maintain an active and productive life style. For these 
patients, an ICD could be considered roughly equivalent to any therapy that reverses an acute 
illness. On the other end of the spectrum is the frail elderly patient with a poor quality of life 
and associated co-morbidities. For such a patient, implantation of an ICD could be a case of 
"too  much,  too  late".                                             
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